Clin Osteol 2005; 10(1): 3-6

Pseudohypoparathyroidism in childhoodArticles

M. Bayer

Pseudohypoparathyroidism (PHP) is characterised by biochemical hypoparathyroidism with elevated parathyroid hormone (PTH) levels and reduced target tissue responsiveness to PTH. Patients with PHP type 1a show a group of developmental defects termed Albright hereditary osteodystrophy (AHO) and exhibit resistance to additional hormones because of heterozygous, inactivating mutation in GNAS1, the gene for the alpha-subunit of the Gs-protein, which disrupts Gs-protein-coupled signal transduction pathways. Within PHP type 1a families some individuals show AHO but have normal hormone responsiveness, a variant phenotype termed pseudo-pseudohypoparathyroidism (PPHP).By contrast, patients with PHP type 1b ma­ nifest only PTH resistance and lack features of AHO. Although an epigenetic defect in GNAS1 has been identified in subjects with PHP1b, the gene­ tic defect is unknown. Patiens with PHP type Ic show both AHO and resistance to multiple hormones with normal Gs-protein activity. Rare PHP type II has no confirmed genetic or familial basis. Patients present additional hormones resistance, normal Gs-protein, and lack AHO phenotype. Treatment of PHP with vitamin D derivatives alleviates symptoms of hypocalcemia and may prevent bone demineral rience with several PHP children.

Keywords: pseudohypoparathyroidism, pseudopseudohypoparathyroidism, Gs-alpha protein, childhood.

Published: June 11, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bayer M. Pseudohypoparathyroidism in childhood. Osteologický bulletin. 2005;10(1):3-6.
Download citation

References

  1. Albright F, Burnett CH, Smith PH. Pseudohypoparathyroidism of "Seabright-Bantam syndrome". Endokrinology 1942;30:922-32.
  2. Spiegel AM, Weinstein LS. Inherited diseases involving g proteins and g prote coupled receptors. Annu Rev Med 2004;55:27-39. Go to original source...
  3. Chase LR, Melson GL, Aurbach GD. Pseudohypoparathyroidism: Defective ex­ cretion of 3',5'-AMP in response to parathyroid hormone. J Clin Invest 1969; 48:1832 44. Go to original source...
  4. Levine MA,Germain-Lee E, Jan de Beur S. Genetic basis for resistence to para­ thyroid hormone. Horm Res 2003;60(Suppl.3):87-95. Go to original source...
  5. Simon A, Kopperschaar HP, Roijers JF, et al. Pseudohypoparathyroidism type Ia. Albright hereditary osteodystrophy: a model for research on ceptors and genomic imprinting. Neth J Med 2000;56:100-109. Go to original source...
  6. Bastepe M, Juppner H. Pseudohypoparathyroidism. New in sease. Endocrinol Metab Clin North Am. 2000;29(3):569-89. Go to original source...
  7. Jan De Beur SM, O'Connell JR, Peila R, et al. The pseudohypoparathyroidism type lb locus is linked to a region including GNAS1 at 20q13.3. J Bone Miner 2003;18:424-33. Go to original source...
  8. Wu WI, Schwindinger WF, Aparicio LF, Levine MA Selective resistence to pa­ rathyroid hormone cause by a novel uncoupling mutation in the karboxyl ter of Gas: A cause of pseudohypoparathyroidism Type Ib. J Biol Chem 2001;276: 165-71. Go to original source...
  9. Liu J, Nealon JG, Weinstein LS. Distinct patterns of abnormal GNAS im in familial and sporadic pseudohypoparathyroidism type IB. Hum Mol Genet 2005;14:95-102. Go to original source...
  10. Linglart A, Carel J., Garabedian M. et al. GNAS1 lesions in pseudohypoparat roidism 1a and 1c: Genotype phenotype relationship and evidence of the maternal transmission of the hormonal resistence. J Clin Endocrinol Metab 2002;87: 189-97. Go to original source...
  11. Divieti P, John MR, Juppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via acti docrinology 2002;143:171-76. Go to original source...
  12. Hatakeyama Y,Mizunashi K, Furukawa Y, et al. Plasma levels of parathyro mone (1-84) whole molecule and parathyroid hormone (7-84)-like fragments in pseudohypoparathyroidism type I. J Clin Endocrinol Metab 2003;88:2250-55. Go to original source...
  13. Bayer M., Kutílek Š. Diferenciálně diagnostické tabulky. In: bolická onemocnení skeletu u dětí, Grada Publishing 2002:323-29.
  14. Marguet C, Naplet E, Basyau JP, et al. Clinical and biological heter pseudohypoparatyroidism syndrome. Results of multicenter study. Horm Res 1997;48:120-30. Go to original source...
  15. Levine MA Parathyroid hormone resistance syndromes. In: Favus MJ. ed. on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. ASBMR 2003:278-85.
  16. Lindsay R, Nieves J, Henneman E, et al. Subcutaneous administration of the no-terminal fragment of human parathyroid hormone (1-34): kinetics and bioche­ mical response in estrogenized osteoporotic patiens. J Clin Endocrinol Metab 1993;77:1535-39. Go to original source...
  17. Lania A, Mantovami G, Spada A Genetics of pituitary tumors: Focus on G-proteins mutations. Exp Biol Med 2003;228:1004-17. Go to original source...
  18. Marie PJ, de Pollak C, Chamsín P, Lomri A Increased proliferation of osteoblas­ tic cells expressing the activating Gs sloha mutation in monostotic and polyo tic fibrous dysplasia. Am J Pathol 1997;150:1059-69.
  19. Yamamoto T, Miyamoto K, Ozono K, et al. Hypophosphatemic rickets accompa­ nying McCune-Albright syndrome: evidence that a humoral factor cause hypo­ phosphatemia. J Bone Miner Metab 2001;19:287-95. Go to original source...
  20. Mahmud FH, Linglart A, Bastepe M, et al. Molecular diagnosis of pseudohypo­ parathyroidism type Ib i trics 2005;115:e342-244.




Clinical Osteology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.